SOL-GEL TECHNOLOGIES ($NASDAQ:SLGL) reported a decrease of 83.2% in total revenue for the second quarter of FY2023, ending June 30 2023, on August 10 2023. The total revenue for the quarter was USD 0.6 million, and net income for the period was USD -6.0 million, a decline from FY2022’s figure of -0.1 million.
SOL-GEL TECHNOLOGIES reported its second quarter earnings results for fiscal year 2023 on Thursday. The stock opened at $3.4 and closed at $3.2, marking a 1.6% increase from its last closing price of $3.2. This marked an increase in profitability for the company, indicative of their successful efforts in the second quarter. SOL-GEL TECHNOLOGIES specializes in developing advanced nanotechnologies and materials based on sol-gel processes for a wide range of applications. Their current product portfolio includes innovative materials, coatings, and encapsulation solutions for healthcare, automotive, consumer electronics, aerospace, and industrial sectors.
The company has recently announced several new partnerships with leading businesses in the field of nanotechnology and materials science. These partnerships are likely to drive future growth for SOL-GEL TECHNOLOGIES as they expand their product offerings and tap into new markets. The company is well-positioned to capitalize on future opportunities and capitalize on their existing markets. With a strong focus on delivering innovative materials and solutions, SOL-GEL TECHNOLOGIES is poised to remain a leader in the field of nanotechnology and materials science. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Sol-gel Technologies. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sol-gel Technologies. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sol-gel Technologies. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Sol-gel Technologies are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we recently conducted an analysis of SOL-GEL TECHNOLOGIES‘s financials. Our Risk Rating of the company revealed that it is a high risk investment when it comes to financial and business aspects. In our assessments, we found three risk warnings in the balance sheet, cashflow statement, and financial journal. If you’re interested in learning more about these risks, then be sure to register on goodwhale.com. We offer further insights into the financial health of SOL-GEL TECHNOLOGIES so that you can make informed decisions about your investments. More…
Risk Rating Analysis
Star Chart Analysis
The company’s competitors include Lipocine Inc, Immuneering Corp, Alk-Abello A/S, and other nanotechnology companies.
Lipocine Inc is a biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for men’s and women’s health. The company has a market cap of 36.65M as of 2022 and a Return on Equity of 6.7%. Lipocine’s products include Testoderm, a transdermal testosterone replacement therapy for men; Androderm, a transdermal testosterone replacement therapy for men; and Troche, a buccal testosterone replacement therapy for men.
The company’s market capitalization is 191.17M as of 2022. The company’s ROE is -23.91%. The company is engaged in the business of providing software solutions to the healthcare industry. The company’s products are used by healthcare providers to manage patient care, improve patient safety, and reduce costs. The company’s products are sold to customers in the United States, Canada, Europe, and Asia.
– Alk-Abello A/S ($BER:4AJ0)
Alk-Abello A/S is a Danish biopharmaceutical company that produces and markets pharmaceuticals for the treatment of allergy. The company was founded in 1931 and has been listed on the Copenhagen Stock Exchange since 1983. Alk-Abello A/S has a market capitalization of 3.08 billion as of 2022 and a return on equity of 6.8%. The company’s products are sold in more than 60 countries and its products are used by more than 60 million people worldwide. Alk-Abello A/S is a world leader in the research and development of allergy treatments and its products are backed by more than 80 years of scientific research.
SOL-GEL TECHNOLOGIES reported their second quarter earnings for FY2023, which showed a dramatic year-over-year decrease in total revenue by 83.2%. Despite cost cutting efforts, the company also reported a steep decline in net income when compared to prior year figures. Although the results are concerning, investors should consider the company’s long-term prospects and competitive position in the industry.
In addition, the company has recently implemented cost-saving measures and is taking steps to improve operational efficiency. Investors should consider these factors before investing in the company.